# A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5

> **NCT02181088** · PHASE1 · COMPLETED · sponsor: **University of Oxford** · enrollment: 26 (actual)

## Conditions studied

- Malaria
- Plasmodium Falciparum

## Interventions

- **BIOLOGICAL:** ChAd63 RH5 low dose
- **BIOLOGICAL:** ChAd63 RH5 full dose
- **BIOLOGICAL:** MVA RH5 low dose
- **BIOLOGICAL:** MVA RH5 full dose

## Key facts

- **NCT ID:** NCT02181088
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2015-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02181088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02181088, "A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02181088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*